Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use-Reference-Cited by-同舟云学术

Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use

Published:2021-01-21 Issue:3 Volume:31 Page:575-586
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Suzuki Yasuo¹,Hirose Tomohiro²³,Sugiyama Noriko⁴,Nomura Kazuto⁵,Campos-Alberto Eduardo³

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Tokyo, Japan

2. Atopy (Allergy) Research Center, Juntendo University School of Medicine, Tokyo, Japan

3. Immunology and Inflammation Medical Affairs, Pfizer Innovative Health, Pfizer Japan Inc, Tokyo, Japan

4. Clinical Statistics, Biometrics and Data Management, Pfizer R&D Japan, Tokyo, Japan

5. Post-Marketing Study Strategy and Management, Development Japan, Pfizer R&D Japan, Tokyo, Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2020.1823604

Reference16 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

3. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis

4. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database

5. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation;RMD Open;2024-03

2. Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review;RMD Open;2024-01

3. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation;2023-12-18